Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu, Lin Shen, Chunmei Bai, Wei Wang, Jie Li, Xianjun Yu, Zhiping Li, Enxiao Li, Xianglin Yuan, Yihebali Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao� Zhang, Dianrong Xiu, Xiuwen Wang, Ying Yuan, Jia Chen, Shukui Qin, Ru Jia, Ming Lu, Yuejuan Cheng, Zhiwei Zhou, Jing Li, James Jun He, Weiguo Su
Topics & Concepts
MedicinePlaceboInternal medicineDiscontinuationClinical endpointInterim analysisPopulationIntention-to-treat analysisProgression-free survivalTolerabilityClinical trialAdverse effectChemotherapyPathologyEnvironmental healthAlternative medicineNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesPancreatic and Hepatic Oncology Research